Nundina › Discover calendars › FDA New Drug Approvals calendar › FDA approves Zanvastro (zilganersen sodium)FDA approves Zanvastro (zilganersen sodium)3 September 2026The FDA approved Zanvastro (zilganersen sodium), a drug from Ionis Pharms Inc. Form: Solution, Intrathecal. Granted priority review, reserved for treatments that would be a significant improvement over what exists. Application NDA220210.FDA New Drug Approvals calendarMore from this calendar

19 October 2026 - FDA approves Calrezdy (calcuim chloride)

19 October 2026 - FDA approves Cienby (sodium ctirate)

16 October 2026 - FDA approves Yulzety (rivaroxaban)

16 October 2026 - FDA approves Brytly (brytly (apraclonidine))

15 October 2026 - FDA approves Evoxac (cevimeline hydrochloride)